Inherited cholesterol disorders remain one of the most underdiagnosed cardiovascular risk conditions in clinical practice, affecting roughly 1 in 250 people for the heterozygous form and 1 in 300,000 for the more severe homozygous variant. This JAMA Insights piece consolidates current clinical standards at a moment when novel lipid-lowering therapies have meaningfully expanded the therapeutic toolkit — making updated guidance practically relevant for millions of unidentified carriers worldwide.
The piece addresses both heterozygous familial hypercholesterolemia (HeFH) and homozygous familial hypercholesterolemia (HoFH), distinguishing their markedly different severity profiles and management needs. HeFH typically presents with LDL-C levels in the 190–400 mg/dL range and is driven by single loss-of-function variants in LDLR, APOB, or PCSK9 genes, while HoFH — caused by biallelic mutations — can produce LDL-C exceeding 500 mg/dL and is associated with accelerated atherosclerosis beginning in childhood. Diagnosis integrates clinical scoring systems such as the Dutch Lipid Clinic Network criteria alongside genetic confirmation, though phenotypic diagnosis remains the more common real-world pathway. Treatment hierarchies discussed include high-intensity statins as first-line agents, with ezetimibe, PCSK9 inhibitors, and emerging agents such as inclisiran and lomitapide addressed for refractory or more severe presentations.
What makes this synthesis particularly useful is the longstanding treatment gap it implicitly highlights: population screening rates for FH remain poor even in high-income countries, and fewer than 10% of those with the condition are estimated to receive a formal diagnosis. From a longevity medicine standpoint, FH represents one of the clearest examples of a monogenic condition where early identification and aggressive LDL lowering produces measurable reductions in premature cardiovascular mortality. The clinical guidance here is consolidatory rather than paradigm-shifting — but its value lies in codifying best practices at a time when the pharmacological options have grown considerably more potent than statins alone.